Cumberland Pharmaceuticals has expanded its medical specialties to include oncology-related medications. The company’s entry into the oncology specialty includes two initial supportive care medications: Ethyol (amifostine) injection and Totect (dexrazoxane hydrochloride) injection. “Since the company’s founding, Cumberland has endeavored to deliver high quality medicines to improve patient care,” said CEO AJ Kazimi. “Our strategy has been to focus on select…